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An internal ribosome entry site in the 5′ untranslated region of
epidermal growth factor receptor allows hypoxic expression
TE Webb, A Hughes, DS Smalley and KA Spriggs
The expression of epidermal growth factor receptor (EGFR/ERBB1/HER1) is implicated in the progress of numerous cancers, a
feature that has been exploited in the development of EGFR antibodies and EGFR tyrosine kinase inhibitors as anti-cancer drugs.
However, EGFR also has important normal cellular functions, leading to serious side effects when EGFR is inhibited. One damaging
characteristic of many oncogenes is the ability to be expressed in the hypoxic conditions associated with the tumour interior. It has
previously been demonstrated that expression of EGFR is maintained in hypoxic conditions via an unknown mechanism of
translational control, despite global translation rates generally being attenuated under hypoxic conditions. In this report, we
demonstrate that the human EGFR 5′ untranslated region (UTR) sequence can initiate the expression of a downstream open
reading frame via an internal ribosome entry site (IRES). We show that this effect is not due to either cryptic promoter activity or
splicing events. We have investigated the requirement of the EGFR IRES for eukaryotic initiation factor 4A (eIF4A), which is an RNA
helicase responsible for processing RNA secondary structure as part of translation initiation. Treatment with hippuristanol (a potent
inhibitor of eIF4A) caused a decrease in EGFR 5′ UTR-driven reporter activity and also a reduction in EGFR protein level. Importantly,
we show that expression of a reporter gene under the control of the EGFR IRES is maintained under hypoxic conditions despite a
fall in global translation rates.
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INTRODUCTION
Epidermal growth factor receptor (EGFR, also ErbB-1 or HER1) is an
important drug target and prognostic indicator in many cancers. It
is a transmembrane glycoprotein tyrosine kinase. Its primary
function is to stimulate Akt-, MAPK- or JNK-mediated cellular
proliferation in response to a range of ligands including
transforming growth factor alpha and the family of EGFs
(reviewed in the study by Oda et al.1).
Overexpression of EGFR has been strongly linked to poor
prognosis in a large number of cancers including breast, head,
neck, ovarian, cervical, bladder and oesophageal cancers
(reviewed in the study by Nicholson et al.2). Mutations in EGFR
have also been shown to be important, for example a subset of
tumours possess a constitutively active truncated version of
EGFR.3 Although there is a strong relationship between the
frequency of this mutation and poor prognosis, possibly more
importantly is overexpression of EGFR with nearly half of
glioblastomas displaying signiﬁcantly elevated levels of the wild-
type receptor.3–9 A major mechanism by which EGFR is over-
expressed is gene ampliﬁcation, as demonstrated in colorectal,
pulmonary, bile duct and soft tissue cancers.10–13 In each of these
instances however, ampliﬁcation was not the only cause of the
overexpression, with a marked discrepancy between gene dosage
and EGFR protein levels.14 While a proportion of this over-
expression may be attributable to mutations that cause the
transcriptional upregulation of the EGFR gene,15–18 it has also
been shown that that EGFR protein levels are upregulated in
response to both hypoxia and the activation of hypoxia-inducible
factor 2α without observing either mutational events or changes
in EGFR mRNA levels.19 Increased EGFR activity is also associated
with Alzheimer’s disease, and inhibiting EGFR reverses amyloid
beta-induced memory loss in mice.20 The untranslated regions
(UTRs) of an mRNA have major roles in the translational control of
its expression. While the 3′ UTR of EGFR has been investigated and
shown to be a target for microRNA-induced suppression under
certain conditions, the 5′ UTR remains largely unstudied.21
In general, cells respond to hypoxia by decreasing protein
synthesis rates.22,23 One mechanism used to accomplish this in the
short term involves the phosphorylation of the translation
initiation factor eIF2α. When hypo-phosphorylated, the function
of eIF2α is to assist in the binding of the initiator transfer RNA to
the 40S ribosomal subunit by forming a ternary complex with GTP.
Phosphorylation of eIF2α inhibits this process, thereby acting as a
brake on global translation rates.24,25
Since internal ribosome entry site (IRES)-mediated translation
initiation does not involve the binding of the 5′ cap, it is favoured
under certain conditions, like hypoxia, that inhibit eukaryotic
initiation factor 4E (eIF4E) function.26–28 Despite this reduced
requirement for eIF4E, it has been demonstrated that the IRESs
belonging to the human genes c-myc, N-myc and BiP have a
strong requirement for eIF4A function for their expression.29–31 It
has been suggested that this requirement indicates that the
structure of these IRESs needs ‘remodelling’ by eIF4A before they
are able to function, similar to the processing required by the
encephalomyocarditis virus IRES.30,32–34
We tested the EGFR 5′ UTR for IRES activity using a dicistronic
reporter system and found that it was able to initiate the
translation of the downstream cistron. Experiments on the EGFR
5′ UTR reporter using the eIF4A inhibitor hippuristanol found that
the EGFR IRES has a high requirement for eIF4A. Finally, we show
School of Pharmacy, University of Nottingham, Nottingham, UK. Correspondence: Dr K Spriggs, School of Pharmacy, University of Nottingham, University Park,
Nottingham NG7 2RD, UK.
E-mail: keith.spriggs@nottingham.ac.uk
Received 2 May 2014; revised 29 September 2014; accepted 15 October 2014
Citation: Oncogenesis (2014) 3, e134; doi:10.1038/oncsis.2014.43
www.nature.com/oncsis
that the EGFR 5′ UTR allows hypoxic expression of a downstream
cistron under conditions where global translation is compromised.
These ﬁndings strongly support the idea that the induction of
EGFR expression in response to hypoxic conditions is attributable
to the presence of a previously unidentiﬁed IRES within its 5′ UTR.
RESULTS AND DISCUSSION
It has previously been shown that EGFR protein levels are
maintained under hypoxic conditions despite a global decrease
in protein synthesis rates, but the mechanism responsible is not
known.19 Moreover, EGFR has recently been shown to be a
regulator of hypoxic microRNA maturation through phosphoryla-
tion of AGO2.35
The EGFR 5′ UTR was cloned between the Renilla and ﬁreﬂy
luciferase open reading frames of pRF and the resultant construct
(pR-EGFR-F) was transfected into human neuroblastoma-derived
SH-SY5Y cells. Parallel control transfections of pRF (a negative
control lacking any IRES element36,37), pRMF (containing the c-myc
IRES36) and pR-Tub-F (containing the β tubulin 5′ UTR, which lacks
IRES activity). The EGFR 5′ UTR permitted the expression of the
downstream cistron in SH-SY5Y cells to a similar extent as the well-
validated c-myc 5′ UTR, whereas the 5′ UTR of β tubulin did not
(Figure 1a.). This effect was also observed in HeLa, Huh7 and MCF7
cells (data not shown). To determine whether cryptic splicing was
occuring (which could lead to functional ﬁreﬂy luciferase
transcripts in the absence of IRES activity) Northern analysis was
performed using a radio-labelled probe against the ﬁreﬂy
luciferase coding region. This conﬁrmed the presence of a single
luciferase containing transcript of the appropriate size in the
transfected cells (Figure 1b). To conﬁrm that the observed activity
was not due to transcription of the ﬁreﬂy luciferase open reading
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Figure 1. The EGFR 5′ UTR sequence permits the expression of the downstream open reading frame of a dicistronic reporter construct without
exhibiting cryptic promoter or splicing activity. The UTRs of β tubulin and EGFR were synthesised by GenScript (Piscataway, NJ, USA) to match
the nucleotide sequences with accession numbers NM_178014.2 and NM_201283.1, respectively. These sequences were ampliﬁed by PCR
using primers containing SpeI restriction sites upstream and NcoI sites downstream, the UTRs were then cloned into pRF between these sites
and the resulting plasmid was termed pR-EGFR-F. The dicistronic reporter containing the c-myc 5′ UTR (pRMF) was as described in a previous
paper.36 The promoter-less version of the dicistronic reporter was created by cloning the two luciferase cistrons, ﬂanking the EGFR 5′ UTR into
a plasmid, which did not contain a promoter sequence. The promoter-less version of the monocistronic reporter was made by cloning the
EGFR 5′ UTR into p15hp in place of the hairpin39 and then disabling the cytomegalovirus promoter by AseI digest. (a, c) A 24-well plate were
seeded with SH-SY5Y cells at a density of 50 000 cells/well. The following day, cells were transfected with 200 ng/well of the plasmids
described above using FuGene 6 (Roche, Mannheim, Germany). The growth medium was changed after 6 h and the cells were cultured for the
following 24 h. Luciferase expression within the cells was then quantiﬁed using a Dual Luciferase Assay Kit (Promega, Madison, WI, USA)
following manufacturer’s instructions. Mean and s.d. of at least three replicates are shown. (b) A Northern blot was performed on lysates from
HeLa cells previously transfected with pRF, pR-EGFR-F or pRMF using a probe complementary to the ﬁreﬂy luciferase open reading frame. The
dicistronic EGFR reporter plasmid generates a single mRNA. (d) The ribosome enters the EGFR 5′ UTR near the start codon. Five mutant
versions of the plasmid pR-EGFR-F were created that contained introduced AUG start codons at different positions within the EGFR 5′ UTR
(mutants are named according to the position of the introduced AUG relative to the wild-type AUG). The introduced AUGs are out-of-frame
with the downstream luciferase gene, therefore, if the ribosome bound to the sequence upstream of one of these, a non-functional protein
would result and quantiﬁed luciferase levels would reduce to background. A 24-well plate was seeded with SH-SY5Y cells. These were allowed
to recover overnight before being transfected with 200 ng/well of the mutant or wild-type reporter plasmids. Twenty-four hours later,
luciferase levels were assayed. Mean and s.d. of at least three replicates are shown.
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frame driven by a cryptic promoter in the EGFR 5′ UTR sequence,
the cytomegalovirus promoter was removed from the dicistronic
constructs by restriction digestion, and the resultant promoter-less
constructs were transfected into SH-SY5Y cells to conﬁrm the
absence of endogenous cryptic promoter activity in any of the 5′
UTR sequences (Figure 1c). We therefore conclude that the
expression of the downstream cistron is directed by an IRES in the
EGFR 5′ UTR.
Having identiﬁed an IRES in the EGFR 5′ UTR, we wished to
determine whether this could further explain previous observa-
tions that increases in EGFR protein can occur without parallel
increases in mRNA.19 Hypoxic conditions (1% O2) caused a
reduction in control Renilla luciferase expression to ~ 50% of its
control value while the expression of the ﬁreﬂy open reading
frames preceded by the EGFR and c-myc 5′ UTR sequences were
maintained (Figure 2). The response of the c-myc IRES to hypoxia
has been documented previously and it is included here as a
positive control.38
To begin to characterise the requirements of the EGFR IRES, we
added 10 μM hippuristanol (a potent and speciﬁc small molecule
inhibitor of eIF4A31) to HeLa cells transfected with the
monocistronic and dicistronic reporters. eIF4A is a DEAD-box
helicase involved in unwinding secondary structure in 5′ UTRs
and is required for efﬁcient cap-independent translation of a
number of transcripts.31,39 This treatment with hippuristanol
revealed a signiﬁcant reduction in EGFR 5′ UTR-mediated
reporter expression (P= 0.007; Figure 3a). The dependency of
the EGFR IRES on eIF4A function is also demonstrated by Western
blot, with hippuristanol causing a dramatic reduction in the
protein level of EGFR, relative to a β tubulin loading control in
HeLa (P= 0.01; Figure 3b).
Iron has been implicated in the function of several IRESes
including those in APP,40 HCV41 and cytoplasmic serine
hydroxymethyltransferase.42 Iron stress is also known to induce
the unfolded protein response,37 which leads to a global reduction
in protein synthesis caused by eIF2alpha phosphorylation.23 EGFR
protein levels speciﬁcally have also been shown to respond to
iron, however, the mechanisms responsible have not previously
been identiﬁed.43,44 We therefore wished to test whether iron has
a speciﬁc effect on EGFR IRES function beyond the general
downregulation of cap-dependent translation caused by
eIF2alpha phosphorylation. SH-SY5Y, HeLa and Huh7 cells were
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Figure 2. Expression of a reporter gene preceded by the 5′ UTR of EGFR is maintained under hypoxic conditions despite a fall in control
reporter expression. (a) A 24-well plate was seeded with SH-SY5Y cells at a density of 50 000 cells/well. The following day, cells were
transfected with 200 ng/well of the plasmids described in the legend of Figure 1 using FuGene 6. The growth medium was changed after 6 h,
and for the following 24 h one of the plates was kept in a control incubator set to atmospheric O2 levels. The other plate was incubated in a
ProOx 110 (BioSpherix Ltd., Lacona, NY, USA) hypoxic chamber which O2 restricted to 1%. Luciferase expression within the cells was then
quantiﬁed using a Dual Luciferase Assay Kit following manufacturer’s instructions. Mean and s.d. of at least three replicates are shown. (b) six-
well plates were seeded with SH-SY5Y cells at a density of 3 × 105 cells/well. The following day, cells were incubated for 24 h at either
atmospheric or 1% O2 levels. EGFR and tubulin protein levels were determined by Western blotting using primary antibodies ab6012 (Abcam,
Cambridge, UK) and sc-7396 (Santa Cruz, Dallas, TX, USA). (c) Four replicates of the blot described in Figure 2b were quantiﬁed using ImageJ
(US National Institutes of Health, Bethesda, Maryland, USA). The data are presented as EGFR expression normalised to tubulin expression. No
signiﬁcant differences in EGFR expression were seen between normoxic (atmospheric) and hypoxic (1% O2) cells.
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treated with 250 μM ammonium iron citrate or control, and a
marked reduction in expression of ﬁreﬂy luciferase expression was
observed from reporters driven by the EGFR 5′ UTR (Figure 3c)
compared with controls. This inhibition was paralleled by a
signiﬁcant reduction in endogenous EGFR expression following
treatment of HeLa cells with 250 μM ammonium iron citrate
(P= 0.02; Figures 3d and e) compared with expression of
beta-tubulin. We have not been able to identify a recognisable
iron response element in the EGFR 5′ UTR primary sequence,
however, it is apparent that the EGFR 5′ UTR confers susceptibility
to iron stress beyond that explained by the modest global
decrease in translation or proliferation exempliﬁed by beta-tubulin
protein levels (Figure 3d). There are precedents for iron levels
inﬂuencing IRES activity40,42 and further work is required to
conﬁrm whether similar mechanisms are at work in EGFR
translational control.
By introducing a series of upstream out-of-frame (relative to
luciferase) AUG start codons into the EGFR 5′ UTR sequence we
have identiﬁed that the 40S ribosomal subunit enters the IRES
between 23 and 56 nucleotide (nt) upstream of the authentic AUG
start codon (Figures 3a and b). Introduction of out-of-frame AUGs
further than 56 nt from the luciferase start codon have no effect
on luciferase expression, indicating that the 40S ribosomal subunit
enters at a position downstream; introduction of an out-of-frame
AUG at position − 20 completely abolishes luciferase expression,
suggesting that the ribosome enters before this position. An
alignment of refseq45 primate EGFR 5′ UTR sequences using
LocARNA46–48 suggests that the ribosome entry region, between
positions − 56 and − 20, may be located within a conserved stem
loop close to the start codon (Figure 4b).
These ﬁndings suggest an opportunity to exploit the hypoxic
control of EGFR translation to develop new targeted therapeutics.
Current therapies such as tyrosine kinase inhibitors or antibodies,
which indiscriminately target EGFR, are associated with a number
of unpleasant and potentially serious side effects.49 Since hypoxia
in otherwise healthy patients is generally restricted to tumour
masses,50 targeting only the hypoxic expression of EGFR offers a
way of restricting EGFR inhibition to tumour masses, allowing
normal expression of EGFR elsewhere in the body and a
consequent reduction in systemic side effects. Although hypoxia
targeting drug delivery systems have been under development for
a number of years,50,51 understanding the mechanisms that allow
hypoxic expression of drug targets is particularly important in
allowing us to directly target gene expression speciﬁcally in
cancer cells.
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Figure 3. (a) EGFR expression is reduced by hippuristanol treatment and iron treatment via its 5′ UTR. Ten micromolar Hippuristanol
(or DMSO) was added to HeLa cells, which were transfected with reporter plasmids 4 h previously. The creation of the reporter plasmid is
described previously (Figure 1.). Luciferase expression was quantiﬁed 24 h later and ﬁreﬂy values were normalised to control Renilla
values (pGL4.80cmv was co-transfected with the monocistronic reporter). Mean and s.d. of at least three replicates are shown. (b) Cellular
lysate was also Western blotted for EGFR and β tubulin using Abcam antibodies ab2430 and ab6046, respectively; representative blots
are pictured. Quantiﬁcation of three replicates of this experiment was performed using ImageJ and the mean expression levels of
EGFR normalised to tubulin were calculated. (c, d) The experiment was repeated as above substituting hippuristanol with 250 μM
of ammonium iron citrate.
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Figure 4. The ribosome enters the EGFR 5′ UTR near the start codon. Five mutant versions of the plasmid pR-EGFR-F were created that
introduced AUG start codons at different positions within the EGFR 5′ UTR (mutants are named according to the position of the introduced
AUG relative to the wild-type AUG). The introduced AUGs are out-of-frame with the downstream luciferase gene, therefore, if the ribosome
bound to the sequence upstream of one of these, a non-functional protein would result and quantiﬁed luciferase levels would reduce to
background. (a) A 24-well plate was seeded with SH-SY5Y cells. These were allowed to recover overnight before being transfected with
200 ng/well of the mutant or wild-type reporter plasmids. After 24 h, luciferase levels were assayed. Mean and s.d of at least three replicates
are shown. (b) Alignment of primate EGFR 5′ UTR refseq sequences using Locarna (Will et al.47,48 and Smith et al.46) suggests that the ribosome
entry site (blue bar) may lie within a conserved stem loop structure near the start codon.
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